EMA Withdrawn: Pregabalin Mylan Pharma (pregabalin) — Mylan S.A.S.

View source ↗

Summary

EMA withdrawal notice for pregabalin marketed by Mylan S.A.S., affecting anxiety disorders, neuralgia, and epilepsy indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Epilepsy
• Neuropathic Pain

Drugs mentioned

• Pregabalin (Pregabalin)

Snippet

Status: Withdrawn. Therapeutic area: Anxiety Disorders;Neuralgia;Epilepsy. MAH: Mylan S.A.S.. Decision date: 14/01/2021